近日,国家医保局公布的新版医保目录中,礼来的替尔泊肽与国产新秀银诺医药的依苏帕格鲁肽α双双被纳入医保,适应证均为2型糖尿病治疗。医保平台上,司美格鲁肽迎来最强竞品替尔泊肽。同时,仁会生物的贝那鲁肽主动退出医保。这些消息如同一颗投入平静湖面的石子,这场医保“入场券”的争夺结果,让竞争日益激烈的新型降糖减重药物GLP-1(胰高血糖素样肽-1受体激动剂)赛道从“蓝海”转向“红海”,预示着中国降糖减重药...
Source Link近日,国家医保局公布的新版医保目录中,礼来的替尔泊肽与国产新秀银诺医药的依苏帕格鲁肽α双双被纳入医保,适应证均为2型糖尿病治疗。医保平台上,司美格鲁肽迎来最强竞品替尔泊肽。同时,仁会生物的贝那鲁肽主动退出医保。这些消息如同一颗投入平静湖面的石子,这场医保“入场券”的争夺结果,让竞争日益激烈的新型降糖减重药物GLP-1(胰高血糖素样肽-1受体激动剂)赛道从“蓝海”转向“红海”,预示着中国降糖减重药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.